UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2017
Taxus Cardium Pharmaceuticals Group, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
001-33635 |
27-0075787 |
|
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer |
|
|
|
|
|
11568 Sorrento Valley Rd., Suite 14 |
|
|
|
San Diego, California |
|
92121 |
|
(Address of principal executive offices) |
|
(Zip Code) |
|
|
||
|
Registrant’s telephone number, including area code: (858) 436-1000 |
||
|
|
||
|
|
||
|
|
||
|
(Former name or former address, if changed since last report.) |
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Scientific American Publishes Article on Angionetic’s Gene Therapy
On January 9, 2017, Taxus Cardium Pharmaceuticals Group Inc. issued a press release announcing an article titled "Heart Therapy," written by Gabor M. Rubanyi, M.D., Ph.D., co-founder of Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (CRXM), which was published in the January 2017 edition of Scientific American.
Item 9.01. Financial Statements and Exhibits.
|
Exhibit No. |
|
Description of Exhibit |
|
99.1 |
|
Press Release |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
||
|
Taxus Cardium Pharmaceuticals Group, Inc. |
||||
|
|
|
|||
|
By: |
|
/s/ Christopher J. Reinhard |
||
|
|
|
Christopher J. Reinhard |
||
|
|
|
Chief Executive Officer |
||
Date: January 9, 2017